ReviewOncotarget2017
Venom-based peptide therapy: insights into anti-cancer mechanism.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 94 citations in OpenAlex.
- In Vitro and In Silico Assessment of Anticancer Activity of Venom-Derived and Biomimetic Neurotransmitter Inhibitor Pentapeptides.Cell biochemistry and biophysics · 2026Article
- Venom-Derived Peptides in Breast Cancer: Pharmacological Mechanisms and Medicinal Chemistry-Guided Translational Development.Archiv der Pharmazie · 2026Review
- Targeting oral squamous cell carcinoma with venom peptides: mechanisms, selectivity and translational potential.The protein journal · 2026Review
- Scorpion Venom as a Source of Cancer Drugs: A Comprehensive Proteomic Analysis and Therapeutic Potential.International journal of molecular sciences · 2025Review
- Article
- Review
- Review
- Wasp Venom: Future Breakthrough in Production of Antimicrobial Peptides.The protein journal · 2025Review
- Use of spheroids as a model to evaluate the anticancer action of animal venoms and derived molecules: 2010-2024 review.The journal of venomous animals and toxins including tropical diseases · 2025Review
- Molecular Display of the Animal Meta-Venome for Discovery of Novel Therapeutic Peptides.bioRxiv : the preprint server for biology · 2024Article
- 3-NAntC: A Potent Crotoxin B-Derived Peptide against the Triple-Negative MDA-MB-231 Breast Cancer Cell Line.Molecules (Basel, Switzerland) · 2024Article
- Peptidome Profiling ofAntibiotics (Basel, Switzerland) · 2024Article
- The effect of Iranian snake,Heliyon · 2024Article
- Cytotoxicity and Radiosensitizing Potentials of Pilosulin-3, a Recombinant Ant Venom, in Breast Cancer Cells.Toxins · 2023Article
- In Silico-Based Design of a Hybrid Peptide with Antimicrobial Activity against Multidrug-ResistantToxins · 2023Article
- Peptides with Diverse Functions from Scorpion Venom: A Great Opportunity for the Treatment of a Wide Variety of Diseases.Iranian biomedical journal · 2023Article
- ApInAPDB: a database of apoptosis-inducing anticancer peptides.Scientific reports · 2022Article
- Evaluation of potential anti-metastatic and antioxidative abilities of natural peptides derived fromPeerJ · 2022Article
- Comparative Snake Venom Analysis for Facilitating Wildlife Forensics: A Pilot Study.Journal of analytical methods in chemistry · 2022Article
- Anti-angiogenic peptides application in cancer therapy; a review.Research in pharmaceutical sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 5-year relative survival rate of all types of cancer has increased significantly over the past three decades partly due to the targeted therapy. However, still there are many targeted therapy drugs could play a role only in a portion of cancer patients with specific molecular alternation. It is necessary to continue to develop new biological agents which could be used alone and/or in combination with current FDA approved drugs to treat complex cancer diseases. Venom-based drugs have been used for hundreds of years in human history. Nevertheless, the venom-origin of the anti-cancer drug do rarely appear in the pharmaceutical market; and this is due to the fact that the mechanism of action for a large number of the venom drug such as venom-based peptide is not clearly understood. In this review, we focus on discussing some identified venom-based peptides and their anti-cancer mechanisms including the blockade of cancer cell proliferation, invasion, angiogenesis, and metastasis (hallmarks of cancer) to fulfill the gap which is hindering their use in cancer therapy. Furthermore, it also highlights the importance of immunotherapy based on venom peptide. Overall, this review provides readers for further understanding the mechanism of venom peptide and elaborates on the need to explore peptide-based therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.